Finance

Beta
Lists
532523:BOM
Biocon Ltd
₹407.30
-1.15%
(-4.75) 1D
Jun 8, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 532523...
Open
₹410.80
High
₹417.10
Low
₹405.90
Mkt. cap
660.52B
Avg. vol.
322.40K
Volume
85.36K
Dividend
0.12%
Quarterly dividend
₹0.13
Ex-dividend date
Jul 3, 2026
P/E ratio
144.43
52-wk high
₹440.30
52-wk low
₹331.00
EPS
₹2.82
Shares outstanding
600.00M
No. of employees
16K
Open
₹410.80
High
₹417.10
Low
₹405.90
Mkt. cap
660.52B
Avg. vol.
322.40K
Volume
85.36K
Dividend
0.12%
Quarterly dividend
₹0.13
Ex-dividend date
Jul 3, 2026
P/E ratio
144.43
52-wk high
₹440.30
52-wk low
₹331.00
EPS
₹2.82
Shares outstanding
600.00M
No. of employees
16K
News stories
From sources across the web
Profile
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. The company was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA. Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
About Biocon Ltd
CEOSiddharth Mittal
Employees16.4K
FoundedNov 29, 1978
HeadquartersBengaluru, Karnataka, India
SectorBiotechnology
Websitebiocon.com
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
39.42B
42.96B
41.73B
45.17B
Cost of goods sold
14.05B
17.72B
13.39B
13.99B
Cost of revenue
14.05B
17.72B
13.39B
13.99B
Research and development expenses
-346.00M
-132.00M
-531.00M
-128.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.33B
9.59B
8.75B
9.12B
Operating expense
22.43B
21.18B
25.16B
26.10B
Total operating expenses
36.48B
38.90B
38.55B
40.10B
Operating income
2.94B
4.05B
3.18B
5.07B
Other non operating income
-11.62B
94.00M
1.17B
525.00M
EBT including unusual items
969.00M
1.71B
-678.00M
2.48B
EBT excluding unusual items
-11.45B
1.23B
2.26B
3.28B
Income tax expense
77.00M
385.00M
-160.00M
489.00M
Effective tax rate
7.95%
22.48%
23.60%
19.76%
Other operating expenses
9.89B
6.72B
11.78B
11.98B
Net income
314.00M
845.00M
1.44B
1.26B
Net profit margin
0.80%
1.97%
3.45%
2.79%
Earnings per share
0.26
0.72
2.74
1.27
Interest and investment income
-
235.00M
-
-
Interest expense
-2.77B
-2.72B
-2.10B
-2.32B
Net interest expenses
-2.77B
-2.49B
-2.10B
-2.32B
Depreciation and amortization charges
4.55B
4.73B
5.15B
5.13B
EBITDA
6.89B
8.69B
7.13B
9.96B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer